US Bioservices is now dispensing VOSEVI

July 28, 2017

The U.S. Food and Drug Administration has approved VOSEVI (sofosbuvir, velpatasir, and voxilaprevir) for the re-treatment of adult patients with chronic hepatitis C (HCV) infection in adults with genotypes 1-6 previously treated with NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.